Glembatumumab vedotin (CDX-011) in Patients with Triple Negative Breast Cancer Over-expressing GPNMB (Currently Enrolling)
This two arm, randomized trial is evaluating the efficacy and safety of Glembatumumab vedotin in patients with metastatic triple negative breast cancer with GPNMB over-expression who have received standard therapies, including anthracycline, if clinically indicated, and taxane treatments. Eligible patients are being randomized to either Glembatumumab vedotin or capecitabine, also known by the trade name Xeloda®, a treatment currently approved by the Food and Drug Administration for the treatment for metastatic breast cancer in a 2:1 fashion. Patients are being treated until disease progression or unacceptable toxicity and all patients will be followed for survival. This trial initiated in December 2013. Please visit www.MetricStudy.com or clinicaltrials.gov for more information on this trial.
Xeloda® is a registered trademark of Genentech, a member of the Roche group.